Pigneux A, et al. - The prospective open-label phase III LAM-SA 2007 (Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old) trial randomly assigned patients to a standard induction regimen with lomustine added or to a consolidation regimen with cytarabine and idarubicin in an attempt to improve the outcome for patients with AML. Adults 60 years of age or older with previously untreated AML who were suitable for intensive chemotherapy and had no unfavorable cytogenetics received standard lomustine chemotherapy (idarubicin, cytarabine and lomustine [ICL]) or without (idarubicin and cytarabine [IC]). The addition of lomustine to standard chemotherapy improved the results of older patients with AML significantly.